Weight-loss drug Wegovy has had a successful relaunch, while diabetes drug Ozempic has seen accelerating growth, Credit Suisse said.
You are here: Home / Credit Suisse upgrades Novo Nordisk on ‘surprise’ growth of obesity and diabetes drugs Ozempic and Wegovy